Zacks Investment Research downgraded shares of AGIOS PHARMACT (AGIO) from NEUTRAL to UNDERPERFORM on March 10, 2014, with a target price of $40.90.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on AGIOS PHARMACT (AGIO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment